Severe Asthma Market to Register Incremental Growth During the Forecast Period (2022-2032), Asserts DelveInsight | Key Companies – GSK, AstraZeneca, Avillion, 4D Pharma, Novartis, Avalo Therapeutics

DelveInsight’s “Severe Asthma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Severe Asthma, historical and forecasted epidemiology as well as the Severe Asthma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Severe Asthma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Severe Asthma Market Insights

Severe Asthma Overview

Asthma is the most common chronic respiratory disease all over the globe. It affects the airways in the lungs, which become inflamed and narrowed due to various triggers, making it harder for air to flow out. It is a complex activity between airway inflammation and airway remodeling that results in airway hyper-responsiveness (AHR), which further leads to variable and excessive airway contraction. The characteristic symptoms of asthma include wheezing, shortness of breath, cough, a sensation of tightness in the chest, straining of neck and chest muscles, rapid breathing, and changes in heart rate.

Some of the key facts of the Severe Asthma Market Report:  

• The Severe Asthma market size was valued at USD 6,706 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032) 
• Severe Asthma is less prevalent than mild and moderate asthma, affecting approximately 10% of all individuals with asthma 
• The total diagnosed prevalent (adult + pediatric) cases of asthma in the 7MM was observed to be 54,215,617 cases in 2021. These cases are expected to increase by 2032 
• Among 7MM, the United States had the highest diagnosed cases of adult asthma with 20,868,845 cases in 2021. The cases are expected to increase by 2032 
• Upcoming Severe Asthma therapies such as GSK3511294 (Depemokimab) and PT010 have the potential to create a significant positive shift in the Severe Asthma market size
• Key Severe Asthma Companies: GSK, AstraZeneca, Avillion, 4D Pharma, Novartis, Avalo Therapeutics, BSI-045B, and others 
• Key Severe Asthma Therapies: GSK3511294 (depemokimab), PT027, PT010, MRx4DP0004, CSJ117 (Ecleralimab), AVTX-002, Biosion, and others 
• The Severe Asthma epidemiology based on type-specific cases analyzed that, the type-specific distribution of the disease suggests an equal prevalence of Type-2 inflammation and non-Type-2 inflammation 

Get a Free sample for the Severe Asthma Market Report 

Key benefits of the Severe Asthma Market report:

1. Severe Asthma market report covers a descriptive overview and comprehensive insight of the Severe Asthma Epidemiology and Severe Asthma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Severe Asthma market report provides insights on the current and emerging therapies.
3. Severe Asthma market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Severe Asthma market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Severe Asthma market.

Severe Asthma Epidemiology Segmentation:

The Severe Asthma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Severe Asthma
• Prevalent Cases of Severe Asthma by severity
• Gender-specific Prevalence of Severe Asthma
• Diagnosed Cases of Episodic and Chronic Severe Asthma

Download the report to understand which factors are driving Severe Asthma epidemiology trends @ Severe Asthma Epidemiological Insights 

Severe Asthma Market  

The dynamics of the Severe Asthma market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

“The pipeline for Severe Asthma is dynamic, consisting of GSK3511294 (Depemokimab) GlaxoSmithKline, PT010 (Breztri/Trixeo/ BGF MDI (budesonide-glycopyrrolate-formoterol inhalation)) AstraZeneca, and PT027 (BDA MDI/Budesonide/albuterol sulfate metered-dose inhaler) AstraZeneca and Bond Avillion which are expected to launch during the forecast period [2022-2032].”

Severe Asthma Market Drivers

• Robust Severe Asthma pipeline
• Improving diagnostic approach
• Increasing demand for personalized therapies
• Increasing Prevalent cases of Severe Asthma

Discover more about therapies set to grab major Severe Asthma market share @ Severe Asthma market forecast  

Severe Asthma Therapies and Key Companies

• GSK3511294 (depemokimab): GSK
• PT027: AstraZeneca/Avillion
• PT010: AstraZeneca
• MRx4DP0004: 4D Pharma
• CSJ117 (Ecleralimab): Novartis
• AVTX-002: Avalo Therapeutics
• Biosion: BSI-045B

Scope of the Severe Asthma Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Severe Asthma Companies: GSK, AstraZeneca, Avillion, 4D Pharma, Novartis, Avalo Therapeutics, BSI-045B, and others
• Key Severe Asthma Therapies: GSK3511294 (depemokimab), PT027, PT010, MRx4DP0004, CSJ117 (Ecleralimab), AVTX-002, Biosion, and others
• Severe Asthma Therapeutic Assessment: Severe Asthma current marketed and Severe Asthma emerging therapies
• Severe Asthma Market Dynamics:  Severe Asthma market drivers and Severe Asthma market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Severe Asthma Unmet Needs, KOL’s views, Analyst’s views, Severe Asthma Market Access and Reimbursement 

Severe Asthma Market Barriers

• High cost of Severe Asthma treatment
• Limitations in Severe Asthma diagnosis
• Incorrect inhaler techniques
• Poor Adherence to treatment

Table of Contents 

1. Severe Asthma Market Report Introduction

2. Executive Summary for Severe Asthma

3. SWOT analysis of Severe Asthma

4. Severe Asthma Patient Share (%) Overview at a Glance

5. Severe Asthma Market Overview at a Glance

6. Severe Asthma Disease Background and Overview

7. Severe Asthma Epidemiology and Patient Population

8. Country-Specific Patient Population of Severe Asthma 

9. Severe Asthma Current Treatment and Medical Practices

10. Severe Asthma Unmet Needs

11. Severe Asthma Emerging Therapies

12. Severe Asthma Market Outlook

13. Country-Wise Severe Asthma Market Analysis (2019–2032)

14. Severe Asthma Market Access and Reimbursement of Therapies

15. Severe Asthma Market Drivers

16. Severe Asthma Market Barriers

17.  Severe Asthma Appendix

18. Severe Asthma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

To know more about Severe Asthma treatment, visit @ Severe Asthma Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com